September 2024 – Page 106

Phenylketonuria Market size is ~ 700 USD million in 2023, as per DelveInsight | PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals

“Phenylketonuria Market”

As per DelveInsight, the Phenylketonuria Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Phenylketonuria in the 7MM.

DelveInsight’s “Phenylketonuria Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Phenylketonuria market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Phenylketonuria market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Key highlights from the Phenylketonuria Market Report:

The 7MM accounted for a market size of approximately 700 USD million in 2023.
Various key players are leading the treatment landscape of phenylketonuria, such as Asubio-Pharma/BioMarin-Pharmaceutical, PTC Therapeutics, Synlogic, and others. The details of the country-wise and therapy-wise market size have been provided below.
In 2023, the United States accounted for the largest market size among the 7MM, making ~60% of the total market size of the 7MM.
Key phenylketonuria companies working in the phenylketonuria market are PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals, and others.
Synlogic’s SYNB1934 is expected to become a key player of the PKU market during the forecast period (2024–2034).
Among the EU4 and the UK, Germany had the largest market size with ~USD 70 million in 2023, while Spain had the smallest market size of PKU.
Among the 7MM, the United States had the highest number of diagnosed prevalent cases of phenylketonuria (PKU) with 18,000 cases in 2023.
The age‐specific data revealed that the highest number of patients affected with PKU was found in the age group of
Currently, the market landscape offers only two approved therapies, both of which are owned by BioMarin. The first is KUVAN (sapropterin), a synthetic form of tetrahydrobiopterin (BH4), which acts by increasing phenylalanine hydroxylase (PAH) activity. The second therapy is PALYNZIQ (pegvaliase), a phenylalanine ammonia-lyase (PAL) enzyme that temporarily restores the levels of PAH and reduces blood phenylalanine concentrations.
In March 2024, PTC submitted a Marketing Authorization Application (MAA) to the EMA for sepiapterin. Additionally, the company anticipates submitting a NDA to the FDA in the third quarter of 2024 and completing regulatory submissions in Japan within the same year
Another drug, Synlogic’s SYNB1934 (Currently in Phase II), is expected to become a key player during the forecast period (2024–2034), owing to its novel MoA, impressive efficacy data, and a patient compliant RoA.
The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of PKU.

Read detailed insights on Phenylketonuria market outlook 2034 @ https://www.delveinsight.com/sample-request/phenylketonuria-pku-market

Phenylketonuria Overview

Phenylketonuria (PKU) is a rare genetic disorder characterized by the accumulation of an amino acid called phenylalanine in the body. Amino acids, which are the building blocks of proteins, are found in all proteins and some artificial sweeteners. PKU can present with a range of symptoms, from mild to severe. The most severe form, known as classic PKU, may not show symptoms until several months after birth. A less severe variant, called variant PKU or non-PKU hyperphenylalaninemia, results in elevated levels of phenylalanine but typically causes only mild symptoms.

PKU is usually diagnosed shortly after birth through neonatal screening programs in many developed countries. In regions with expanded newborn screening, PKU is detected by measuring phenylalanine (Phe) and tyrosine (Tyr) levels in dried blood spots using tandem mass spectrometry. The traditional bacterial inhibition assay (Guthrie test) is a manual and semi-quantitative method that has been largely replaced by more modern, automated techniques. Some laboratories now employ fluorimetric tests, which are quantitative, automated, and reliable.

Sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4), has been introduced as a supplementary treatment alongside dietary management for PKU. BH4 is a natural cofactor for the enzyme phenylalanine hydroxylase (PAH), which converts phenylalanine into tyrosine. In individuals with PKU, PAH activity is deficient or absent. BH4 supplementation can help activate any residual PAH enzyme activity, enhancing the metabolism of phenylalanine and reducing its levels in some patients.

KUVAN (sapropterin) is an approved treatment for PKU. By providing the BH4 cofactor, KUVAN helps to improve the oxidative metabolism of phenylalanine, thereby lowering phenylalanine levels in certain individuals with the condition.

Phenylketonuria Epidemiology Insights:

Most cases of phenylketonuria (PKU) are identified in infants due to widespread newborn screening programs. Data indicate that the majority of PKU patients are aged 14 years or younger, representing nearly 60% of cases across the seven major markets (7MM) in 2023.
According to DelveInsight’s estimates, in 2023, missense mutations accounted for 60% of the total diagnosed PKU cases in the 7MM, while nonsense mutations represented 5%.
Among the EU4 countries and the UK, Germany reported the highest number of diagnosed PKU cases, followed by France. Spain had the fewest cases in 2023.

In the United States, classic PKU was the most prevalent form, with approximately 11,000 cases recorded in 2023.

Phenylketonuria Marketed Therapies

KUVAN (Sapropterin Hydrochloride): Asubio-Pharma/BioMarin-Pharmaceutical
PALYNZIQ (pegvaliase-pqpz/rAvPAL-PEG/BMN 165): BioMarin Pharmaceutical

Phenylketonuria Emerging Therapies

Sepiapterin (PTC923): PTC Therapeutics
SYNB1934: Synlogic

Learn How the Phenylketonuria Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/phenylketonuria-pku-market

Phenylketonuria Market Outlook

The primary objective of PKU treatment is to maintain plasma phenylalanine levels between 120−360 µmol/L (2−6 mg/dL), typically achieved through a meticulously planned and monitored diet.

In 2007, the US FDA approved KUVAN (sapropterin hydrochloride) for the treatment of PKU. KUVAN is an oral formulation of tetrahydrobiopterin (BH4), a natural cofactor for the PAH enzyme, which helps enhance the activity of any residual PAH enzyme, facilitating the conversion of phenylalanine into tyrosine. KUVAN is used alongside a phenylalanine-restricted diet and is produced by BioMarin Pharmaceutical. However, KUVAN is not effective for all PKU patients and shows the best results in children with mild forms of the disorder.

Research is ongoing to identify additional treatment options for PKU. These include large neutral amino acid supplementation, which may reduce the brain’s uptake of phenylalanine, and enzyme replacement therapy, which aims to introduce a substance that mimics the action of the enzyme responsible for breaking down phenylalanine.

Current studies indicate that PKU treatment involves a combination of approaches. The development pipeline includes several potential monotherapies. The PKU therapeutics market is anticipated to expand significantly during the forecast period (2024–2034).

Leading Players in the Phenylketonuria Therapeutics Market Include:

Phenylketonuria Companies working in the market are PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals, and others.

Phenylketonuria Report Covers the In-depth Assessment of the Emerging Phenylketonuria Drugs & Key Companies. Download the Phenylketonuria Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/phenylketonuria-pku-market

Table of Contents

1. Key Insights

2. Executive Summary

3. Phenylketonuria Competitive Intelligence Analysis

4. Phenylketonuria Market Overview at a Glance

5. Phenylketonuria Disease Background and Overview

6. Phenylketonuria Patient Journey

7. Phenylketonuria Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Phenylketonuria Treatment Algorithm, Current Treatment, and Medical Practices

9. Phenylketonuria Unmet Needs

10. Key Endpoints of Phenylketonuria Treatment

11. Phenylketonuria Marketed Products

12. Phenylketonuria Emerging Drugs and Latest Therapeutic Advances

13. Phenylketonuria Seven Major Market Analysis

14. Attribute Analysis

15. Phenylketonuria Market Outlook (In US, EU5, and Japan)

16. Phenylketonuria Access and Reimbursement Overview

17. KOL Views on the Phenylketonuria Market

18. Phenylketonuria Market Drivers

19. Phenylketonuria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Phenylketonuria Market size is ~ 700 USD million in 2023, as per DelveInsight | PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals

Dry Eye Disease Market Size was valued ~4 billion in 2023 to grow from 2024 to 2034, DelveInsight Reports | Alcon/Aerie Pharma, Mitotech, BRIM Biotechnology, Taejoon Pharma, Allysta Pharma

The Dry Eye Disease Market Forecast-2034 report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the 7MM.

DelveInsight’s “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Dry Eye Disease, offering comprehensive insights into the Dry Eye Disease revenue trends, prevalence, and treatment landscape. The report delves into key Dry Eye Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dry Eye Disease therapies. Additionally, we cover the landscape of Dry Eye Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dry Eye Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dry Eye Disease space.

To Know in detail about the Dry Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Eye Disease Market Forecast

Some of the key facts of the Dry Eye Disease Market Report:

The Dry Eye Disease market size was valued ~USD 4 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the Dry Eye Disease (DED) market size in the EU4 and the UK was USD 821 million, with expectations of substantial growth at a notable CAGR.
In the 7MM, Japan held the third-largest market share, amounting to USD 199 million in 2023.
Key Dry Eye Disease Companies: Alcon/Aerie Pharmaceuticals, Mitotech, BRIM Biotechnology, Inc., Taejoon Pharmaceutical Co., Ltd, Allysta Pharmaceutical, Invirsa, Inc., Ocugen, Invirsa, Inc., Oculis, Telios Pharma, Inc., ORA, Inc., IVIEW Therapeutics, Senju Pharmaceutical, and others
Key Dry Eye Disease Therapies: AR-15512, SkQ1 eye drops, BRM421, TJO-083, ALY688, INV-102, Brimonidine, licaminlimab, TL-925, ST-100 (vezocolmitide), IVW-1001, LME636, SJP-0132, and others
The Dry Eye Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
In January 2024, Alcon, based in Switzerland, announced that its dry eye disease medication AR-15512 met its primary endpoints in two Phase III trials, COMET-2 and COMET-3. Following these positive results, the company intends to submit a New Drug Application (NDA) for AR-15512 to the FDA by mid-2024, as stated in a press release on January 9. The COMET-2 (NCT05285644) and COMET-3 (NCT05360966) trials, which were vehicle-controlled, included over 930 patients aged 30 and older with dry eye disease.
In April 2024, Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical firm specializing in pioneering medications that target the melanocortin receptor system, has announced the presentation of topline results from its Phase 3 PL9643 MELODY-1 trial. This pivotal study assesses the safety and effectiveness of PL9643 compared to a vehicle in treating dry eye disease (DED). The results were showcased at the American Society of Cataract and Refractive Surgery (ASCRS).
According to DelveInsight’s assessment, the estimated total diagnosed prevalent cases of Dry Eye Disease across the 7MM were approximately 54.7 million in 2023.
In 2023, among European countries, the United Kingdom reported the highest number of diagnosed prevalent cases of Dry Eye Disease, with approximately 6.1 million cases, followed by Germany with about 5.0 million cases. Conversely, Spain had the lowest number of prevalent cases, totaling around 2.1 million.
The US had the highest proportion of total diagnosed prevalent cases of Dry Eye Disease among the 7MM countries in 2023, accounting for 41%, while Japan reported the lowest at 19%. This trend is expected to continue throughout the forecast period.
In the US, diagnosed prevalent cases of Dry Eye Disease were approximately 9,439 thousand for males and about 13,035 thousand for females in 2023. Projections suggest that by 2034, the prevalence among females will exceed that of males.

Dry Eye Disease Overview

Dry Eye Disease (DED) is a common condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to dryness, irritation, and inflammation. Symptoms often include a feeling of dryness or grittiness in the eyes, redness, blurred vision, and discomfort. Causes can range from environmental factors and medications to underlying health conditions. Treatment typically involves using artificial tears, lifestyle changes, and, in more severe cases, prescription medications or surgical options.

Get a Free sample for the Dry Eye Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dry-eye-disease-market-insights

Dry Eye Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dry Eye Disease Epidemiology Segmentation:

The Dry Eye Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of DED in the 7MM
Gender-specific Diagnosed Prevalent Cases of DED in the 7MM
Age-specific Diagnosed Prevalent Cases of DED in the 7MM
Severity-specific Diagnosed Prevalent Cases of DED in the 7MM

Download the report to understand which factors are driving Dry Eye Disease epidemiology trends @ Dry Eye Disease Epidemiology Forecast

Dry Eye Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Eye Disease market or expected to get launched during the study period. The analysis covers Dry Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dry Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dry Eye Disease Therapies and Key Companies

AR-15512: Alcon/Aerie Pharmaceuticals
SkQ1 eye drops: Mitotech
BRM421: BRIM Biotechnology, Inc.
TJO-083: Taejoon Pharmaceutical Co., Ltd
ALY688: Allysta Pharmaceutical
INV-102: Invirsa, Inc.
Brimonidine: Ocugen
INV-102: Invirsa, Inc.
licaminlimab: Oculis
TL-925: Telios Pharma, Inc.
ST-100 (vezocolmitide): ORA, Inc.
IVW-1001: IVIEW Therapeutics
LME636: Alcon
SJP-0132: Senju Pharmaceutical

Discover more about therapies set to grab major Dry Eye Disease market share @ Dry Eye Disease Treatment Landscape

Dry Eye Disease Market Strengths

Dry eye is a highly prevalent condition, affecting a significant portion of the population, particularly with advancing age. This prompts a substantial need for methods of diagnosis, treatment, and management solutions.
Various treatment options for dry eye syndrome are available, including artificial tears, prescription drugs, eyelid hygiene products, and punctal plugs, allowing for tailored approaches to management.

Dry Eye Disease Market Opportunities

Increased public education campaigns can further raise awareness of dry eye and encourage people to seek help.
Collaboration among pharmaceutical companies, research institutions, and healthcare providers can facilitate the development of novel therapies and diagnostic tools for Dry Eye Disease.

Scope of the Dry Eye Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dry Eye Disease Companies: Alcon/Aerie Pharmaceuticals, Mitotech, BRIM Biotechnology, Inc., Taejoon Pharmaceutical Co., Ltd, Allysta Pharmaceutical, Invirsa, Inc., Ocugen, Invirsa, Inc., Oculis, Telios Pharma, Inc., ORA, Inc., IVIEW Therapeutics, Senju Pharmaceutical, and others
Key Dry Eye Disease Therapies: AR-15512, SkQ1 eye drops, BRM421, TJO-083, ALY688, INV-102, Brimonidine, licaminlimab, TL-925, ST-100 (vezocolmitide), IVW-1001, LME636, SJP-0132, and others
Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Dry Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Dry Eye Disease Market Access and Reimbursement

To know more about Dry Eye Disease companies working in the treatment market, visit @ Dry Eye Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Dry Eye Disease Market Report Introduction

2. Executive Summary for Dry Eye Disease

3. SWOT analysis of Dry Eye Disease

4. Dry Eye Disease Patient Share (%) Overview at a Glance

5. Dry Eye Disease Market Overview at a Glance

6. Dry Eye Disease Disease Background and Overview

7. Dry Eye Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Dry Eye Disease

9. Dry Eye Disease Current Treatment and Medical Practices

10. Dry Eye Disease Unmet Needs

11. Dry Eye Disease Emerging Therapies

12. Dry Eye Disease Market Outlook

13. Country-Wise Dry Eye Disease Market Analysis (2020–2034)

14. Dry Eye Disease Market Access and Reimbursement of Therapies

15. Dry Eye Disease Market Drivers

16. Dry Eye Disease Market Barriers

17. Dry Eye Disease Appendix

18. Dry Eye Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Eye Disease Market Size was valued ~4 billion in 2023 to grow from 2024 to 2034, DelveInsight Reports | Alcon/Aerie Pharma, Mitotech, BRIM Biotechnology, Taejoon Pharma, Allysta Pharma

Dental Implants Professionals Introduces Comprehensive Dental Implant Solutions in Melbourne

Dental Implants Professionals offers quality, affordable dental implants in Melbourne, ensuring patient comfort and long-lasting results. Led by Dr. Paulo Pinho, our expert team provides personalised care with sedation options.

Sydney, NSW – September 5, 2024 – Dental Implants Professionals, a leading provider of high-quality dental implant services, is proud to announce the availability of affordable dental implants in Melbourne. The practice, known for its patient-focused approach and exceptional care, is dedicated to offering superior dental implant treatments that ensure long-lasting results and enhanced oral health.

Dental-Implants-in-Melbourne

“At Dental Implants Professionals, we understand the importance of maintaining a healthy smile and the confidence that comes with it. Our team of highly qualified dental professionals is committed to delivering the best possible care to patients seeking dental implants in Melbourne. We are dedicated to making the dental implant process as smooth and comfortable as possible, ensuring that patients can enjoy the city’s attractions even shortly after their procedure.”

“Our cheapest dental implants Melbourne services are designed to provide a permanent solution to missing teeth, offering stability and support that removable dentures cannot match. We use only the highest quality implants that meet Australian dental standards, ensuring that each patient receives a durable and natural-looking replacement for their missing tooth. Our dental implants not only restore the functionality of the teeth but also enhance the overall appearance of the smile, allowing patients to eat, speak, and smile with confidence.”

Understanding that dental procedures can be intimidating, especially for those with anxiety or nervousness, they offer sedation options, including sleep dentistry, to ensure a relaxing experience. Their dental surgeons have extensive experience in oral surgery and are well-equipped to handle even the most complex cases with care and precision.

Patients visiting their clinic in Melbourne can expect a thorough consultation, during which their experts will carefully assess their dental health and discuss the best treatment options available with the dental implants price Melbourne. They take the time to explain every step of the process, answering any questions and addressing any concerns to ensure that their patients feel fully informed and comfortable with their treatment plan.

Dental Implants Professionals is committed to providing affordable dental implant solutions without compromising on quality. They believe that everyone deserves access to top-tier dental care, and they strive to make their dental implants cost Melbourne as cost-effective as possible. Whether people need a single implant or multiple replacements, their team is here to help people achieve a healthy, beautiful smile.

About Dental Implants Professionals:

Established in 2009, Dental Implants Professionals is a premier dental practice specialising in dental implants in Melbourne. Their mission is to provide high-quality, affordable dental care to patients from all over Australia. Led by Dr. Paulo Pinho, a seasoned oral surgeon with over a decade of experience, they are dedicated to delivering exceptional results and ensuring patient satisfaction. Their clinic is equipped with state-of-the-art technology, and their team is committed to staying at the forefront of dental advancements. They are proud to offer personalised care that meets the unique needs of each patient.

To learn more, visit https://dentalimplantscost.com.au/.

Media Contact
Company Name: Dental Implants Professionals
Contact Person: Paulo Pinho
Email: Send Email
Phone: 1300 850 072
Address:2/9 York Street
City: Sydney
State: New South Wales
Country: Australia
Website: https://www.dentalimplantscost.com.au/

Attorney Mario T. Milano to Speak at JPPCLE’s 40th Annual Seminar

Attorney Mario T. Milano is honored to be a topic speaker at the highly anticipated 40th Annual Seminar hosted by the Joint Patent Practice Continuing Legal Education (JPPCLE)

New York, NY – September 5, 2024 – Attorney Mario T. Milano is honored to be a topic speaker at the highly anticipated 40th Annual Seminar hosted by the Joint Patent Practice Continuing Legal Education (JPPCLE). The event will take place on September 10th, 2024, in New York, NY. Remote registration is available via Zoom for those who cannot attend in person.

The JPPCLE Annual Seminar is a prestigious event that gathers top legal professionals, patent practitioners, and intellectual property experts from across the nation to discuss current trends, challenges, and advancements in the field of patent law. As one of the keynote speakers, Mario T. Milano will bring his extensive experience and deep understanding of patent law to the seminar, providing valuable insights and thought-provoking discussions to attendees.

Mario T. Milano, a respected patent attorney with a proven track record in intellectual property law, is known for his ability to navigate complex legal landscapes and deliver strategic solutions for his clients. His participation in the JPPCLE Annual Seminar underscores his commitment to advancing the field of patent law and sharing his expertise with fellow practitioners.

Event Details:

• Date: September 10th, 2024

• Time: 8:30 AM – 5:30 PM

• Location: New York City Bar Association, 42 West 44th Street, New York, NY 10036

• Remote Registration: Available via Zoom

Registration Link: JPPCLE 40th Annual Joint Patent Practice Seminar

The seminar will cover a broad range of topics essential to patent practice, including recent legal developments, strategic patent prosecution, enforcement strategies, and emerging issues in intellectual property law. Attendees will have the opportunity to engage with industry leaders, participate in interactive sessions, and expand their professional network.

Mario T. Milano’s session aims to equip attendees with practical knowledge and innovative approaches to managing patent portfolios and navigating the intricacies of intellectual property law.

“Being part of the JPPCLE Annual Seminar is a significant opportunity to contribute to the ongoing dialogue in patent law and to connect with other professionals who are dedicated to excellence in this field,” said Mario T. Milano. “I look forward to sharing insights and learning from the collective expertise of the attendees.”

The JPPCLE 40th Annual Seminar promises to be an enriching experience for all participants, offering a platform for knowledge exchange and professional growth. Don’t miss the chance to hear from leading experts like Mario T. Milano and gain valuable insights that can enhance your practice.

About The Law Office of Mario T Milano:

Mario Milano is a skilled patent attorney offering customized IP strategies for clients, from solo inventors to large corporations. Specializing in diverse technologies, he strengthens patent applications with real-world expertise, handles USPTO filings, manages international portfolios, and assists with patent sales and licensing to maximize IP value.

Contact Information

For more information about Mario Milano Law and the services they offer, please visit https://mariomilanolaw.com/.

Media Contact
Company Name: The Law Office of Mario T Milano LLC
Contact Person: Mario Milano
Email: Send Email
Phone: +1 (856) 433-1618
Address:332 Knoll Top Ln
City: Haddonfield
State: NJ
Country: United States
Website: https://mariomilanolaw.com/

ThreatBook is Recognized as a Strong Performer in Gartner® Peer Insights™ Voice of the Customer for Network Detection and Response

ThreatBook, a global leading provider of AI-driven threat detection and response solutions, has been named as a Strong Performer in the 2024 Gartner® Peer Insights™ Voice of the Customer for Network Detection and Response (NDR) for the second consecutive year.

The “Voice of the Customer” is a report that synthesizes Gartner Peer Insights’ reviews from real customers targeting vendors, for IT decision makers. This report contains highly detailed responses and ratings from clients regarding every aspect of NDR product, is complementary to Gartner expert research and can play a key role in the buying process of security and risk management leaders, as it focuses on direct peer experiences of implementing and operating a solution.

From 26 customer reviews over an 18-month period ending June 30, 2024, ThreatBook received the title of “Strong Performer” with an overall rating of 4.8 out of 5 and a 97% “Willingness to Recommend” rating—the second highest among nine vendors that met the report’s inclusion criteria. We believe these underscore the robust performance of our threat detection platform TDP, and the superior user experience we provide.

Customers from various industries and organizations have shared their positive experiences with the ThreatBook TDP on the Gartner Peer Insights. In one review, the head of security at a bank gave perfect scores in all categories and commented: “It has accurate alerts and good usability, saving our security team from alert fatigue”.

In another review, the Director of IT Security and Risk Management at a manufacturing company also gave top marks across the board and highlighted TDP’s comprehensive asset discovery capabilities: “Threat detection is highly accurate, identifying targeted attacks and avoiding alert noise. In addition, the sorting out of assets is comprehensive, and automatic risk warning can be carried out”.

ThreatBook TDP is a network detection and response platform with TI inside that delivers the most effective network security capabilities with high-fidelity detection of sophisticated attacks and automated response to help organizations address the core challenges of frontline security operations. Since its launch, ThreatBook TDP has been recognized by global enterprises for its more accurate detection capabilities, better user experience, and stronger advanced threat detection capabilities, and the product now serves customers across industries such as manufacturing, finance, and energy.

About ThreatBook

ThreatBook, founded in 2015, is a leading provider of cyber threat detection and response. We pioneered new approaches to deliver high-fidelity, efficient and actionable security intelligence and integrated the ability with full life cycle threat detection system and incident response capabilities to empower the protection on cloud, network and endpoints, help enterprises achieve high efficiency of responding to threats, reduce complexity and improve security operations.

Disclaimer

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Media Contact
Company Name: ThreatBook
Contact Person: Evan Liao
Email: Send Email
City: Singapore
Country: Singapore
Website: https://www.threatbook.com

Play Like a Pro, Save Like a Genius: INNOCN’s 27 Inch OLED QHD Monitor (27A1S) – The Top Budget-Friendly Pick for National Video Game Day

Shenzhen, China – September 5, 2024 – With National Video Game Day just around the corner on September 12th, INNOCN is excited to offer gamers a game-changing upgrade that combines top-tier performance with unbeatable value: the INNOCN 27″ OLED QHD Gaming Monitor (Model 27A1S). This monitor is not only an exceptional performer but also the most budget-friendly high-quality OLED gaming monitor available today.

Imagine experiencing your favorite games with a breathtaking 2560 x 1440p resolution and stunning OLED visuals that bring every pixel to life. The INNOCN 27″ OLED QHD Gaming Monitor boasts a jaw-dropping 240Hz refresh rate and an ultra-fast 0.03ms response time, ensuring that every action, from the quickest maneuvers to the most intense battles, is displayed with unparalleled clarity and smoothness.

What truly sets this monitor apart is its OLED technology. OLED (Organic Light-Emitting Diode) provides an exceptional contrast ratio and vibrant colors that are simply unmatched by traditional LED screens. With OLED, you experience deeper blacks and brighter whites, creating a more dynamic and immersive gaming environment. This technology also allows for faster pixel response times and wider viewing angles, meaning every detail remains sharp and vivid, whether you’re right in front of the screen or sharing the view with friends.

Why settle for anything less when you can have top-tier quality without the hefty price tag? This monitor offers gamers a chance to enjoy the exceptional OLED technology and superior performance without stretching their budget. It’s the perfect choice for both casual players looking to enhance their experience and dedicated esports enthusiasts seeking an edge in competitive play.

Seamless connectivity is a breeze with HDMI, DisplayPort, and USB Type-C options, while the built-in stereo speakers add immersive sound to your gaming adventures. Plus, the height-adjustable stand ensures you can find the perfect viewing angle for those marathon gaming sessions.

As National Video Game Day approaches, there’s no better time to upgrade your gaming setup. Embrace the thrill of high-quality visuals and smooth gameplay with the INNOCN 27″ OLED QHD Gaming Monitor. Celebrate this special day with a monitor that delivers both exceptional performance and incredible value.

Make National Video Game Day unforgettable! Upgrade your gaming rig with the INNOCN 27″ OLED QHD Monitor and experience unmatched visuals and performance at an unbeatable price. Act now and level up your game!

Don’t miss out on this opportunity to transform your gaming experience. Explore more and seize this fantastic deal now at Amazon Link.

PRODUCT LINK:

27A1S: https://www.amazon.com/dp/B0CMSVLJW2

About INNOCN

INNOCN is a trailblazer in display technology, committed to delivering innovative and high-performance solutions that redefine visual experiences. With a focus on quality and advancement, INNOCN continues to lead the industry in creating displays that set new standards for excellence.

Media Contact:

Manufacturer’s Name: Shenzhen Century Joint Innovation Technology Company Limited (INNOCN)

Manufacturer’s Official Website: https://www.innocn.com

Manufacturer’s Email Address: marketing@innocn.com

Media Contact
Company Name: Shenzhen Century Joint Innovation Technology Company Limited
Contact Person: Media Relations
Email: Send Email
Country: China
Website: https://www.innocn.com

Obesity Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novo Nordisk, Boehringer Ingelheim, Pfizer, BioAge Labs, Aphaia Pharma, Neothetics, NovMetaPharma, Carmot

The Obesity Market Forecast-2034 report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the 7MM.

DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Obesity, offering comprehensive insights into the Obesity revenue trends, prevalence, and treatment landscape. The report delves into key Obesity statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Obesity therapies. Additionally, we cover the landscape of Obesity clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Obesity treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Obesity space.

To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast

Some of the key facts of the Obesity Market Report:

The Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
Key Obesity Companies: Novo Nordisk, Boehringer Ingelhium, Pfizer, BioAge Labs, Aphaia Pharma US LLC, Neothetics, Inc, NovMetaPharma Co., Ltd, Carmot Therapeutics, Inc., Aardvark Therapeutics, Inc., Glyscend, Inc., Palatin Technologies, Inc, Regor Pharmaceuticals Inc., and others
Key Obesity Therapies: Oral semaglutide, Survodutide (BI 456906), Danuglipron (PF-06882961), Azelaprag (BGE-105), APHD-012, LIPO-102, Cyclo-Z, CT-868, ARD-101, GLY-200, Bremelanotide, RGT001-075, and others
The Obesity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obesity pipeline products will significantly revolutionize the Obesity market dynamics.
In June 2024, Researchers at the Children’s Hospital of Philadelphia (CHOP) have uncovered how a molecule regulates insulin sensitivity, which could lead to new therapeutic targets for type 2 diabetes related to obesity.
In June 2024, In the first quarter of 2024, Novo Nordisk and Eli Lilly led the obesity market, with Novo Nordisk earning $6.3 billion and Eli Lilly $2.3 billion in sales from their weight-loss medications.
In June 2024, The US House Ways and Means Committee has suggested a plan for Medicare to include coverage for GLP-1 weight-loss medications such as Wegovy and Zepbound.
In June 2024, Zealand Pharma has announced a share issuance to raise DKK 7 billion ($1 billion) to support the development of its obesity treatment candidates.
In June 2024, Form Health secured $38 million in a Series B funding round to advance its evidence-based obesity care programs and improve its telehealth platform.
In June 2024, Novo Nordisk revealed a $4.1 billion investment to construct a new factory in North Carolina, aiming to boost production of Wegovy and Ozempic.
In June 2024, Researchers discovered that the decrease in coronary heart disease rates among individuals under 60 in the UK has plateaued, likely due to increasing obesity rates.
In June 2024, At the ADA’s 84th Scientific Sessions, three studies highlighted new developments in drug therapies for obesity, including findings on GLP-1 receptor agonists.
In June 2024, Palatin Technologies, a biopharmaceutical firm focused on pioneering treatments that target the melanocortin receptor system, has launched a Phase II clinical study of bremelanotide for obesity treatment. Approved by the FDA, the trial will evaluate the effectiveness, safety, and tolerability of bremelanotide when used in conjunction with tirzepatide, a GLP-1/GIP therapy, in patients with obesity.
In 2023, the total number of prevalent obesity cases in the United States was approximately 114 million. According to DelveInsight’s estimates, this number is projected to rise by 2034.
In the United States, the treatment rate for children with obesity was lower compared to adults, with an estimated 6,000 children receiving treatment for obesity in 2023.
In 2023, approximately 360,000 adults with obesity received treatment, and this number is projected to grow by 2034.
In 2023, there were approximately 2,500,000 cases of obesity across the EU4 countries and the UK, with Germany reporting the highest number of cases.

Obesity Overview

Obesity is a medical condition characterized by excessive accumulation of body fat that can negatively impact health. It is typically measured using the Body Mass Index (BMI), where a BMI of 30 or higher indicates obesity. Obesity can lead to various health problems, including heart disease, diabetes, and high blood pressure. It is often influenced by a combination of genetic, behavioral, and environmental factors, including poor diet, lack of physical activity, and hormonal imbalances.

Get a Free sample for the Obesity Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Obesity Epidemiology

Obesity Epidemiology Segmentation:

The Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalent Cases of Obesity in the 7MM
Total Obesity patients seeking help in the 7MM
Total Treated Cases of Obesity in the 7MM

Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Epidemiology Forecast

Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to get launched during the study period. The analysis covers Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obesity Therapies and Key Companies

Oral semaglutide : Novo Nordisk
Survodutide (BI 456906): Boehringer Ingelhium
Danuglipron (PF-06882961): Pfizer
Azelaprag (BGE-105): BioAge Labs
APHD-012: Aphaia Pharma US LLC
LIPO-102: Neothetics, Inc
Cyclo-Z: NovMetaPharma Co., Ltd
CT-868: Carmot Therapeutics, Inc.
ARD-101: Aardvark Therapeutics, Inc.
GLY-200: Glyscend, Inc.
Bremelanotide: Palatin Technologies, Inc
RGT001-075: Regor Pharmaceuticals Inc.

Discover more about therapies set to grab major Obesity market share @ Obesity Treatment Landscape

Obesity Market Strengths

There has been an increase in pharmaceutical companies’ investment in the research and development of drugs.
New and emerging mobile technologies are providing unprecedented possibilities for understanding and intervening in obesity

Obesity Market Opportunities

Several key pharmaceutical players such as Novo Nordisk, Eli Lilly and Company, and others have taken the initiative to meet the unmet needs of the obesity market’s present situation.
Many government and nongovernment bodies are trying to make the patients aware of obesity. This will expand the market further as such patients will seek appropriate treatment.

Scope of the Obesity Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Obesity Companies: Novo Nordisk, Boehringer Ingelhium, Pfizer, BioAge Labs, Aphaia Pharma US LLC, Neothetics, Inc, NovMetaPharma Co., Ltd, Carmot Therapeutics, Inc., Aardvark Therapeutics, Inc., Glyscend, Inc., Palatin Technologies, Inc, Regor Pharmaceuticals Inc., and others
Key Obesity Therapies: Oral semaglutide, Survodutide (BI 456906), Danuglipron (PF-06882961), Azelaprag (BGE-105), APHD-012, LIPO-102, Cyclo-Z, CT-868, ARD-101, GLY-200, Bremelanotide, RGT001-075, and others
Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Obesity Unmet Needs, KOL’s views, Analyst’s views, Obesity Market Access and Reimbursement

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment

Table of Contents

1. Obesity Market Report Introduction

2. Executive Summary for Obesity

3. SWOT analysis of Obesity

4. Obesity Patient Share (%) Overview at a Glance

5. Obesity Market Overview at a Glance

6. Obesity Disease Background and Overview

7. Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of Obesity

9. Obesity Current Treatment and Medical Practices

10. Obesity Unmet Needs

11. Obesity Emerging Therapies

12. Obesity Market Outlook

13. Country-Wise Obesity Market Analysis (2020–2034)

14. Obesity Market Access and Reimbursement of Therapies

15. Obesity Market Drivers

16. Obesity Market Barriers

17. Obesity Appendix

18. Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novo Nordisk, Boehringer Ingelheim, Pfizer, BioAge Labs, Aphaia Pharma, Neothetics, NovMetaPharma, Carmot

DRA Family Office Initiative Launches Female Founders Institute to Support Women Entrepreneurs

Rose Vitale, Managing Partner of DRA Family Office

SAN DIEGO – Sep 5, 2024 – DRA Family Office Initiative today announced the launch of the Female Founders Institute, a pioneering program whose mission is to empower women entrepreneurs. Taking inspiration from DRA Family Office Managing Partner Rose Vitale, a successful entrepreneur turned private investors, the Institute’s goal is to bridge the gender gap in entrepreneurship by providing women with vital resources, mentorship, and funding opportunities.

“There’s so much talent and potential in the universe of women entrepreneurs,” Vitale explained. “However, taking a business from idea to success often requires mentoring from women who have walked this path before. That’s what we’re doing with the Female Founders Institute. We combine practical guidance with encouragement and access to a network of partners and investors who can help turn dreams into realities.”

Empowering Women Entrepreneurs

The Female Founders Institute offers a comprehensive suite of services tailored specifically for women, including high-quality mentorship from experienced entrepreneurs, specialized training programs, networking events, and potential funding through partnerships with leading venture capital firms.

A Vision for Inclusivity and Growth

Recognizing the unique challenges faced by women entrepreneurs, such as limited access to capital and networks, the DRA Family Office Initiative is committed to fostering an inclusive and supportive ecosystem. “Women entrepreneurs are key drivers of economic innovation and social change. Our goal is to create an environment where they can thrive,” said Vitale.

Program Highlights

The Institute is offering a variety of programs for women entrepreneurs, including:

Mentorship Programs: Participants will be paired with experienced mentors who offer guidance and industry insights.
Educational Workshops: Workshops will cover essential skills such as business planning, financial management, marketing, and leadership.
Networking Events: Regular events will facilitate connections with investors, industry experts, and potential partners.
Access to Capital: The program will connect participants with venture capital firms and angel investors committed to supporting women-led businesses.
Collaborative Workspace: A state-of-the-art workspace will be available for collaboration and growth.

Commitment to Long-Term Impact

The DRA Family Office Initiative aims to ensure the long-term success of the Female Founders Institute by continually evolving the program based on feedback and industry trends. “By investing in women entrepreneurs, we are investing in a more diverse, equitable, and prosperous future,” added Vitale.

About DRA Family Office Initiative

The DRA Family Office Initiative is dedicated to fostering innovation and driving inclusive growth. With a focus on sustainable and impactful investments, it aims to create lasting value for future generations.

For more information, visit https://drafamilyoffice.com

Media Contact
Company Name: DRA Family Office
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://drafamilyoffice.com/

Psoriasis Market is anticipated to rise at a notable CAGR, estimates DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb

“Psoriasis Market”

As per DelveInsight, the Psoriasis Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Psoriasis in the 7MM.

DelveInsight’s “Psoriasis Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Psoriasis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Psoriasis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Key highlights from the Psoriasis Market Report:

In October 2023, the US FDA approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe psoriasis in adults who are candidates for systemic therapy or phototherapy. It is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis.
The launch of potential therapies by key players AnaptysBio, MoonLake Immunotherapeutics, Takeda, Evelo Biosciences, UNION Therapeutics, and others are expected to boost the psoriasis market in the coming years.
AnaptysBio intends to out-license imsidolimab in 2024 and the company plans to present the data in second half of 2024 medical meeting.
In February 2023, Nimbus Therapeutics announced the closing of Takeda’s acquisition of Nimbus Lakshmi and its tyrosine kinase 2 (TYK2) inhibitor program, which includes the oral, selective allosteric TYK2 inhibitor NDI-034858, now known as TAK-279.
In July 2020, the US FDA granted ODD for imsidolimab for treating patients with generalized pustular psoriasis.
Key Psoriasis Companies: Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, and others
Key Psoriasis Therapies: TLL018 tablets, Rimegepant, SFA002, BMS-986165, BMS-986322, VTX958, Apremilast, Risankizumab, ESK-001, DC-806, Bimekizumab, JNJ-77242113, Topical roflumilast, Imsidolimab, Tildrakizumab, Secukinumab, PF-07038124, Spesolimab, KBL697, Orticumab, ATI-450, and others
The Psoriasis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psoriasis pipeline products will significantly revolutionize the Psoriasis market dynamics.
In June 2023, UCB, declared that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with the U.S. Food & Drug Administration (FDA). UCB previously communicated the FDA action was expected in Q2, 2023. UCB now anticipates the FDA action in Q3, 2023. There are no open Information Requests from the FDA regarding the BLA for bimekizumab.

Read detailed insights on Psoriasis market outlook 2034 @ https://www.delveinsight.com/sample-request/psoriasis-market

Psoriasis Overview

Psoriasis is a chronic autoimmune condition that affects the skin, causing inflammation, redness, and the development of scaly patches. This widespread disorder impacts millions of people worldwide. The core issue in psoriasis is an overactive immune response that accelerates the skin cell growth cycle, leading to the rapid buildup of thick, silvery scales on the skin’s surface. While symptoms can vary, common signs include red patches covered with thick, white or silvery scales, itching, burning sensations, dry and cracked skin that may bleed, and swollen, stiff joints. Psoriasis can appear anywhere on the body but commonly affects areas such as the elbows, knees, scalp, lower back, and nails.

The exact cause of psoriasis is not fully understood, but it is thought to result from a combination of genetic factors and environmental triggers. Diagnosis typically involves a dermatologist evaluating the affected skin and reviewing the patient’s medical history. Although no specific diagnostic test exists for psoriasis, a skin biopsy may be performed to exclude other skin conditions. The severity of psoriasis is often assessed using various classification systems that consider the extent of skin involvement and the impact on the patient’s quality of life.

Psoriasis Epidemiology Insights:

Psoriasis is a widespread condition with a global prevalence ranging from 1% to 8%, and approximately one-third of cases begin in childhood.
In 2023, the total number of diagnosed psoriasis cases in the US was estimated to be around 8 million.
Among type-specific cases, plaque psoriasis is the most common, affecting approximately 68% of patients, followed by inverse psoriasis.
In 2023, about 28% of psoriasis patients in the US were estimated to have genital psoriasis, with scalp psoriasis being another prevalent form.
Plaque psoriasis is the most common type, affecting about 90% of psoriasis patients, with 20%–30% experiencing moderate to severe forms.
A study by Armstrong et al. (2021) examined the prevalence of psoriasis among adults in the US and noted trends since 2003. The study found a 3.0% prevalence rate for adults, while the prevalence among children under 18 years was approximately 0.128%.

Psoriasis Therapies

TLL018 tablets
Rimegepant
SFA002
BMS-986165
BMS-986322
VTX958
Apremilast
Risankizumab
ESK-001
DC-806
Bimekizumab
JNJ-77242113
Topical roflumilast
Imsidolimab
Tildrakizumab
Secukinumab
PF-07038124
Spesolimab
KBL697
Orticumab
ATI-450

Psoriasis Key Companies

Hangzhou Highlightll Pharmaceutical Co. Ltd
Biohaven Pharmaceuticals, Inc.
SFA Therapeutics
Bristol-Myers Squibb
Ventyx Biosciences, Inc
Amgen
AbbVie
Alumis Inc
DICE Therapeutics, Inc.
UCB Pharma
Janssen Research & Development, LLC
Arcutis Biotherapeutics, Inc.
AnaptysBio, Inc.
Sun Pharmaceutical Industries Limited
Novartis
Pfizer
Boehringer Ingelheim
KoBioLabs
Abcentra
Aclaris Therapeutics

Learn How the Psoriasis Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/psoriasis-market

Psoriasis Market Outlook

Psoriasis is a chronic, relapsing skin condition requiring ongoing management, influenced by disease severity, comorbidities, and healthcare access. Patients are generally classified into mild or moderate-to-severe categories based on lesion severity, affected body surface area, and quality of life impact. The psoriasis treatment market is largely driven by TNF inhibitors, interleukin inhibitors, and vitamin D analogs, with growth fueled by the adoption of biologics, precision medicine, and expanded topical treatments. Recent market developments include the approval of oral TYK2 inhibitors and nonsteroidal topical agents, increasing competition.

Key psoriasis treatments include:

– BIMZELX (bimekizumab-bkzx): A monoclonal antibody targeting moderate to severe plaque psoriasis by inhibiting IL-17A and IL-17F. Approved by the US FDA in October 2023 for adults needing systemic or phototherapy.

– ENBREL (etanercept): A TNF blocker that combines the TNF receptor’s ligand-binding portion with human IgG1’s Fc portion.

– REMICADE (infliximab): A TNF blocker for severe adult plaque psoriasis, consisting of a chimeric IgG1κ monoclonal antibody with both human and murine components.

– HUMIRA (adalimumab): A recombinant human IgG1 monoclonal antibody created through phage display technology, combining human-derived and human constant regions.

– STELARA (ustekinumab): Targets IL-12 and IL-23 cytokines using a human IgG1κ monoclonal antibody, produced through recombinant DNA technology.

– COSENTYX (secukinumab): A human biologic that inhibits IL-17A, impacting various conditions including psoriatic arthritis and moderate to severe plaque psoriasis.

Psoriasis Treatment Market

A variety of treatments are available for managing psoriasis symptoms. For mild-to-moderate cases, topical therapies are typically used. These treatments aim to modulate gene transcription, inhibit cell proliferation, and promote keratinocyte differentiation. Common topical options include glucocorticoids, vitamin D analogs, and phototherapy. Notable agents in this category are corticosteroids, retinoids such as tazarotene, calcineurin inhibitors like tacrolimus, and vitamin D analogs such as calcipotriene and calcitriol. Combination therapies, such as calcipotriene with betamethasone dipropionate, are also used.

For patients who do not respond adequately to traditional systemic therapies, or who experience adverse effects or have comorbidities that make such therapies unsuitable, biologics offer a potent alternative. These advanced treatments target specific immune system components involved in psoriasis.

Several biosimilars are available for treating psoriasis and psoriatic arthritis, providing options similar to established biologics. Biosimilars to HUMIRA (adalimumab) include AMJEVITA (adalimumab-atto), ABRILADA (adalimumab-afzb), CYLTEZO (adalimumab-adbm), HADLIMA (adalimumab-bwwd), HULIO (adalimumab-fkjp), and HYRIMOZ (adalimumab-adaz). For ENBREL (etanercept), biosimilars include ERELZI (etanercept-szzs) and ETICOVO (etanercept-ykro). Biosimilars for REMICADE (infliximab) are AVSOLA (infliximab-axxq), INFLECTRA (infliximab-dyyb), IXIFI (infliximab-qbtx), and RENFLEXIS (infliximab-abda).

Leading Players in the Psoriasis Therapeutics Market Include:

Psoriasis Companies working in the market are Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, and others.

Psoriasis Report Covers the In-depth Assessment of the Emerging Psoriasis Drugs & Key Companies. Download the Psoriasis Market Sample Report to Learn More @ https://www.delveinsight.com/sample-request/psoriasis-market

Table of Contents

1. Key Insights

2. Executive Summary

3. Psoriasis Competitive Intelligence Analysis

4. Psoriasis Market Overview at a Glance

5. Psoriasis Disease Background and Overview

6. Psoriasis Patient Journey

7. Psoriasis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Psoriasis Treatment Algorithm, Current Treatment, and Medical Practices

9. Psoriasis Unmet Needs

10. Key Endpoints of Psoriasis Treatment

11. Psoriasis Marketed Products

12. Psoriasis Emerging Drugs and Latest Therapeutic Advances

13. Psoriasis Seven Major Market Analysis

14. Attribute Analysis

15. Psoriasis Market Outlook (In US, EU5, and Japan)

16. Psoriasis Access and Reimbursement Overview

17. KOL Views on the Psoriasis Market

18. Psoriasis Market Drivers

19. Psoriasis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Market is anticipated to rise at a notable CAGR, estimates DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb

Biopolymers Market is Estimated to Reach USD 35.60 Billion 2031, Supported by Environmental Supremacy

“Skyquest Technology”

Biopolymers Market Size, Share, Growth Analysis, By Type (Biodegradable, PLA), By Application (Films, Bottle), By End Users (Packaging, Consumer Goods), By Region – Industry Forecast 2024-2031

Biopolymers Market was valued at USD 15.60 billion in 2022 and is poised to grow from USD 17.10 billion in 2023 to USD 35.60 billion by 2031, growing at a CAGR of 9.60% in the forecast period (2024-2031).

Biopolymers are synthetic materials derived from plant-based sources such as residual wood and lumber, and agricultural commodities such as sugarcane, maize, and others. Biopolymers, unlike standard polymers or plastics, are naturally biodegradable. The market is growing due to changing consumer tastes for environmentally friendly plastic products. This increased consumer awareness of sustainable plastic alternatives, combined with unstoppable activities to reduce the use of traditional plastics that are non-biodegradable, speeds up the commercial development of bioplastics. Standard plastics, primarily produced from oil, take some time before they break down and decompose, resulting in a lot of time spent in landfills.

Download a detailed overview:

https://www.skyquestt.com/sample-request/biopolymers-market

Top Player’s Company Profiles

BASF SE
NatureWorks LLC
Braskem SA
Total SE
Arkema SA
Corbion NV
Novamont S.p.A.
Mitsubishi Chemical Corporation
DuPont de Nemours, Inc.
Eastman Chemical Company
Biome Bioplastics Limited
Plantic Technologies Limited
Danimer Scientific, Inc.
Rodenburg Biopolymers BV
KANEKA Corporation
Bio-On S.p.A.
BioBag International AS
Innovia Films Ltd.
Toray Industries, Inc.
Solanyl Biopolymers Inc.

Cutting Plastic Pollution: The Role of New Biomaterials in Eco-Conscious Fast-Food Packaging

New non-polluting biomaterials are being developed to replace traditional fossil-based plastic coatings found in grease-resistant fast-food packaging. While the typical coating for grease-resistant paper contains plastic and other harmful substances, including polyfluoroalkyl substances, this new prototype coating manages to fulfill all functional requirements set by traditional grease-resistant packaging materials as an environmentally sustainable solution. Hence, the outcome of this will be major steps toward making a sustainable, green, and conscientious biopolymer for the future. Natural polymers generated from seaweed serve as feedstock for the new coating formulation. Depending on the application, these extracts are modified using a unique processing technology to produce functional biopolymer sheets that can be sliced or coated on a variety of surfaces.

Strategic Moves in Biopolymers: Mergers, Acquisitions, and Expansions by Industry Giants

The global biopolymers market is highly fragmented and competitive. To increase their market share, large multinational firms employ a variety of business tactics, including mergers and acquisitions, expansions, and investments. NatureWorks, Braskem, BASF, and Total Corbion are some of the world’s leading bioplastics and biopolymers manufacturers. Leading companies launch new products to increase their market position and customer base.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/biopolymers-market

Segments covered

Product

Bio-PE, Bio-PET, PLA, PHA, Biodegradable Plastics and Other

Application

Films, Bottle, Fibers, Seed Coating, Vehicle Components, Medical Implants and Other

End Users

Packaging, Consumer Goods, Automotive, Textiles, Agriculture and Others

Significant Recent Developments in Biopolymer Solutions

July 2024: Neste and Mitsubishi Corporation announced a strategic partnership to develop a renewable chemicals and plastics supply chain for Japanese brand owners. With this agreement, the companies hope to target brand owners in industries such as food and beverage, clothing, and consumer electronics.
June 2024: BASF Chemical Company announced the inclusion of a biomass balanced ecoflex polybutylene adipate terephthalate (PBAT) variant to their biopolymer portfolio. The new product is the ecoflex F Blend C1200 BMB, designed to substitute fossil raw materials with renewable feedstock in the process of their production.
February 2024: Khalifa Economic Zones Abu Dhabi Group is now in a partnership with Gulf Biopolymers Industries and will be joining the industry ecosystem of KEZAD.The GBI intends to establish a factory in the Middle East to produce biodegradable and recyclable polylactic acid polymers.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/biopolymers-market

Sustainable Packaging and Medical Advances: The Dual Impact of Biopolymers Currently, all major F&B manufacturers use plastic, and they are all well-positioned to move to bioplastic packaging. As a result, once commercial bioplastics is developed, the bioplastics sector is predicted to grow. Governments across the globe are initiating biopolymer projects. Biopolymers find applications in the production of medical devices, which are used to either replace or restructure imperfect, injured, or dead tissue or parts of bones, such as joints, heart valves, arteries, teeth, and tendons and ligaments in connective tissue; and eye lenses. This growth has been swift due to aging populations and technical changes in medical devices.

Related Reports:

Cyber Security Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/biopolymers-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biopolymers Market is Estimated to Reach USD 35.60 Billion 2031, Supported by Environmental Supremacy